세계의 데컴병 시장 예측(-2030년)

Market Overview

The Dercum's Disease Market is anticipated to register a CAGR of 6.76% during the forecast period. The rising predominance of interesting diseases and expanding research and advancement exercises are driving market development.

Uncommon diseases, for example, adiposis dolorosa, and lipomas alongside the continuous Coronavirus pandemic, represent a significant weight worldwide. As per the NCBI study, held in February 2021, roughly 2500 individuals each year with free connective (fat) tissue disease were seen, most patients with lipedema, six patients with FML-Type DD, and 10 patients with angiolipoma-type Dercum's disease. Moreover, a similar review recommended that the predominance of Dercum's disease is 0.64% in the populace, and the commonness of lipedema in the USA is believed to be 11% in ladies however the reach is 5 to 39%. A greater part of individuals with dercum's disease are ladies.

Besides, dercum's disease is portrayed by various, agonizing developments of greasy tissue (lipomas). In this way, the quantity of patients experiencing uncommon diseases is expanding universally. Besides, the rising instances of Coronavirus likewise fundamentally affect the market development of the dercum's disease. Such an ascent in the quantity of diseases cases is expected to worldwide expand the interest for dercum's disease.

Market Segmentation

The Market segments of Dercum's Disease, based on treatment, includes surgery, medication, liposuction, electrotherapy, acupuncture, and others.

The Dercum's Disease Market segmentation is based on end user that includes hospital & clinics ambulatory surgical centers others. Based on distribution channel the market is divided into hospital pharmacies, retail pharmacies, and others.

Regional Insights

The North America dercum's disease market represented the biggest market share in 2022. This is because of the ideal government act towards for the improvement of uncommon disease drug and gadgets as well as endorsement of medication in the district.

Europe dercum's disease market represents the second-biggest market share because of the research concentrates on through medical services administrative bodies for the therapy of dercum's disease and ideal approach and public undertakings systems. further, the Germany market of dercum's disease was credited to hold the biggest market share, and the France market of dercum's disease is supposed to quickest developing market in the European locale.

The Asia-Pacific dercum's disease market is supposed to develop at a critical offer from 2023 to 2030. This is because of the rising speculation, clinical preliminary examinations, and organizations' Research and development for medications to treat fat dolorosa in the Asia-Pacific locale.

The Rest of the World is portioned into the Middle East, Africa, and Latin America. The market of dercum's disease in the previously mentioned locales is probably going to observe development because of raising of assets and interests in the area through organizations.

Major Players

Key Companies in the market of dercum's disease include Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
  • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.4 FORECASTING TECHNIQUES
• 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.5.1 BOTTOM-UP APPROACH
  • 3.5.2 TOP-DOWN APPROACH
• 3.6 DATA TRIANGULATION
• 3.7 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF RARE DISEASES
  • 4.2.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
• 4.3 RESTRAINTS
  • 4.3.1 LACK OF AWARENESS AMONG THE PEOPLE ABOUT THE DISEASE
• 4.4 OPPORTUNITIES
  • 4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 SALES AND DISTRIBUTION
  • 5.1.4 POST-SALES REVIEW
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL DERCUM'S DISEASE MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON DEMAND
  • 5.3.3 IMPACT ON MARKET

6 GLOBAL DERCUM'S DISEASE MARKET, BY TREATMENT

• 6.1 OVERVIEW
• 6.2 SURGERY
• 6.3 MEDICATION
  • 6.3.1 DIURETICS
  • 6.3.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUG
  • 6.3.3 CORTICOSTEROIDS
  • 6.3.4 OTHERS
• 6.4 LIPOSUCTION
• 6.5 ELECTROTHERAPY
• 6.6 ACUPUNCTURE
• 6.7 OTHERS

7 GLOBAL DERCUM'S DISEASE MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 HOSPITAL & CLINICS
• 7.3 AMBULATORY SURGICAL CENTERS
• 7.4 OTHERS

8 GLOBAL DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACIES
• 8.3 RETAIL PHARMACIES
• 8.4 OTHERS

9 GLOBAL DERCUM'S DISEASE MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 FINANCIAL MATRIX
  • 10.3.1 SALES (USD MILLION), 2022
  • 10.3.2 R&D EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

• 11.1 PFIZER INC
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 ABBVIE, INC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 KEY STRATEGIES
• 11.3 JOHNSON & JOHNSON SERVICES, INC
  • 11.3.1 COMPANY OVERVIEWS
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 GLAXOSMITHKLINE PLC
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 BAUSCH & LOMB INCORPORATED
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTSS
  • 11.5.5 KEY STRATEGIES
• 11.6 CALIWAY
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS/SERVICES OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 RAZIEL THERAPEUTICS LTD
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 NIVARTA, INC.
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 BHR PHARMACEUTICALS LTD
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY STRATEGIES
• 11.10 NOVARTIS INTERNATIONAL AG
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS